Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 8/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 7/20 | 0.41 |
| ▸ | IDO1 | P14902 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401659 | 0.90 | MAP2K1 (0.52) | NOTUMMAP2K1MAP2K2IDO1MAPK1 | |
| SCHEMBL6137711 | 0.81 | MAP2K1 (0.40) | MAP2K1MAP2K2IDO1MEN1KMT2A | |
| SCHEMBL6137781 | 0.81 | MAP2K1 (0.43) | MAP2K1MAP2K2IDO1MEN1KMT2A | |
| SCHEMBL6137572 | 0.81 | MAP2K1 (0.40) | MAP2K1MAP2K2IDO1MEN1KMT2A | |
| SCHEMBL6137791 | 0.75 | MAP2K1 (0.41) | MAP2K1MAP2K2IDO1MEN1KMT2A | |
| SCHEMBL6137886 | 0.75 | MAP2K1 (0.39) | MAP2K1MAP2K2IDO1MEN1KMT2A | |
| SCHEMBL6137953 | 0.75 | MAP2K1 (0.41) | MAP2K1MAP2K2IDO1MEN1KMT2A | |
| SCHEMBL6137793 | 0.74 | MAP2K1 (0.38) | MAP2K1MAP2K2IDO1MEN1KMT2A | |
| SCHEMBL6137852 | 0.74 | MAP2K1 (0.40) | MAP2K1MAP2K2IDO1MEN1KMT2A | |
| SCHEMBL6137905 | 0.74 | KDM4E (0.40) | MAP2K1MAP2K2MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1144394-B1 | 1-HETEROCYCLE SUBSTITUTED DIARYLAMINES | WARNER LAMBERT CO (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6545030-B1 | Treating proliferative diseases, the sequelae of a stroke or heart failure, xenograft rejection, osteoarthritis, HIV, rheumatoid arthritis, cystic fibrosis, hepatomegaly, shock,cardiomegaly, Alzheimer's disease, diabetes | WARNER-LAMBERT COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-20030004193-A1 | 1-Heterocycle substituted diarylamines | BARRETT STEPHEN DOUGLAS (US) | 2003-01-02 | — | — | US | disclosed |
| EP-1202732-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1144394-A1 | 1-HETEROCYCLE SUBSTITUTED DIARYLAMINES | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001005391-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2000042029-A1 | 1-HETEROCYCLE SUBSTITUTED DIARYLAMINES | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004193-A1 | 1-Heterocycle substituted diarylamines | IDH3A, CCNA1, HCCS | NOTUM 4168/4885MAP2K1 3800/4885MAP2K2 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.